Physician profile
Nana E Tchabo
NPI 1851508436
$1,639.08
in general payments reported to CMS, 2019-2025
21 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.30 · 2020: $29.19 · 2021: $108 · 2023: $422 · 2024: $515 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $369.50 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $355.18 | 2021-2025 | Jemperli, Zejula, Shingrix |
| Daiichi Sankyo INC. | $229.46 | 2023-2025 | Enhertu, Vanflyta |
| Mirati Therapeutics, INC. | $153.17 | 2023-2024 | Krazati |
| Eisai INC. | $81.65 | 2023-2025 | |
| Kerecis Limited | $59.36 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Davol INC. | $52.03 | 2025 | Arista |
| Astellas Pharma US INC | $41.09 | 2023 | Xospata |
| Incyte Corporation | $38.00 | 2025 | Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $35.08 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $32.51 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $32.23 | 2023-2024 | Lynparza, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $23.18 | 2023 | Vpriv |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Janssen Biotech, INC. | $18.33 | 2024 | Talvey, Tecvayli, Darzalex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $17.41 | 2023 | Xpovio |
| Tersera Therapeutics LLC | $17.00 | 2023 | Zoladex |
| Recordati_rare_diseases_inc. | $16.82 | 2024 | Sylvant |
| Genzyme Corporation | $16.52 | 2025 | |
| Abbvie INC. | $16.35 | 2025 | |
| Emd Serono, INC. | $15.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nana Tchabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.